Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.57 |
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | ALB | P02768 | 2/20 | 0.46 |
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22402546 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1EPHX2ALB | |
| SCHEMBL15507483 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1EPHX2ALB | |
| SCHEMBL24173761 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1EPHX2ALB | |
| SCHEMBL15507479 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1EPHX2ALB | |
| SCHEMBL24174150 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1EPHX2ALB | |
| SCHEMBL24173323 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1EPHX2ALB | |
| SCHEMBL24558475 | 0.94 | GLP1R (0.54) | GLP1RNOD1FOLH1EPHX2ALB | |
| SCHEMBL21938093 | 0.94 | GLP1R (0.54) | GLP1RNOD1FOLH1EPHX2ALB | |
| SCHEMBL21242702 | 0.94 | GLP1R (0.54) | GLP1RNOD1FOLH1EPHX2ALB | |
| SCHEMBL18488491 | 0.94 | GLP1R (0.54) | GLP1RNOD1FOLH1EPHX2ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259856-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2019-04-16 | — | — | US | disclosed |
| US-9688737-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2017-06-27 | — | — | US | disclosed |
| EP-2254906-B1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2016-10-05 | — | — | EP | disclosed |
| US-20150210747-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2015-07-30 | — | — | US | disclosed |
| US-9045560-B2 | Protease stabilized, acylated insulin analogues | NOVO NORDISK A/S (DK) | 2015-06-02 | — | — | US | disclosed |
| US-20140073564-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2014-03-13 | — | — | US | disclosed |
| US-20130143798-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143798-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, GCG, IAPP | GLP1R 1/4885NOD1 1083/4885FOLH1 251/4885 |
| US-20150210747-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 54/4885NOD1 3835/4885FOLH1 524/4885 |
| US-20140073564-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 84/4885NOD1 3929/4885FOLH1 408/4885 |
| US-10259856-B2 | Protease stabilized acylated insulin analogues | IAPP, IDE, LIPE | GLP1R 54/4885NOD1 3835/4885FOLH1 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.